GRCE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Grace Therapeutics, Inc (GRCE) is not a good buy for a beginner, long-term investor at this time. The technical indicators suggest a lack of upward momentum, options data shows bearish sentiment, and the company's financial performance is weak with declining net income and EPS. While there was an earnings beat, the lack of strong positive catalysts and no significant trading signals make this stock unsuitable for the user's investment profile.
The MACD is negative and expanding downward, indicating bearish momentum. RSI is neutral at 38.922, and moving averages are converging, showing no clear trend. The stock is trading below its pivot point of 3.636, with support at 3.491 and resistance at 3.781.
The company reported an earnings beat for Q3 2026, which has slightly increased market interest.
The company has declining financials, including a 44.28% YoY drop in net income and a 61.11% YoY drop in EPS. Cash reserves are also decreasing, and no significant insider or hedge fund activity has been observed.
In Q3 2026, revenue remained stagnant at $0, net income dropped by 44.28% YoY to -$2.315 million, and EPS fell by 61.11% YoY to -$0.14. Cash and cash equivalents decreased from $22.1 million in March 2025 to $18.7 million in December 2025, indicating financial strain.
No recent analyst rating or price target changes are available for GRCE.
